215 related articles for article (PubMed ID: 22123870)
21. Effects of Two Different Exogenous Surfactant Preparations on Serial Peripheral Perfusion Index and Tissue Carbon Monoxide Measurements in Preterm Infants with Severe Respiratory Distress Syndrome.
Terek D; Gonulal D; Koroglu OA; Yalaz M; Akisu M; Kultursay N
Pediatr Neonatol; 2015 Aug; 56(4):248-55. PubMed ID: 25603725
[TBL] [Abstract][Full Text] [Related]
22. In response to mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.
Egan EA
J Perinatol; 2013 Feb; 33(2):165-6. PubMed ID: 23361501
[No Abstract] [Full Text] [Related]
23. Bovine or Porcine: Does the Type of Surfactant Matter?
Boshoff Coyles L; Joolay Y; Tooke L
J Trop Pediatr; 2020 Oct; 66(5):534-541. PubMed ID: 32112649
[TBL] [Abstract][Full Text] [Related]
24. Choosing a right surfactant for respiratory distress syndrome treatment.
Ramanathan R
Neonatology; 2009; 95(1):1-5. PubMed ID: 18832858
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy and safety of late surfactant preparations: a retrospective study.
Lane MD; Kishnani S; Udemadu O; Danquah SE; Treadway RM; Langman A; Balevic S; Jackson WM; Laughon M; Hornik CP; Greenberg RG; Clark RH; Zimmerman KO
J Perinatol; 2021 Nov; 41(11):2639-2644. PubMed ID: 34285358
[TBL] [Abstract][Full Text] [Related]
26. Comparison of efficacy between beractant and poractant alfa in respiratory distress syndrome among preterm infants (28-33
Zamal A; Sk MH; Saha B; Hazra A
J Perinatol; 2024 Apr; ():. PubMed ID: 38609483
[TBL] [Abstract][Full Text] [Related]
27. On "A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants" (Am J Perinatol 2004;21:109-120).
Bancalari E
Am J Perinatol; 2004 Jul; 21(5):307-9. PubMed ID: 15232767
[No Abstract] [Full Text] [Related]
28. Poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
Dizdar EA; Sari FN; Oguz SS; Dilmen U
J Paediatr Child Health; 2013 Dec; 49(12):1084. PubMed ID: 24325724
[No Abstract] [Full Text] [Related]
29. Comparison of Efficacy and Pharmacoeconomic Outcomes Between Calfactant and Poractant Alfa in Preterm Infants With Respiratory Distress Syndrome.
Bui A; Schumann C; Le J; Jones T; Schwendeman C
J Pediatr Pharmacol Ther; 2024 Jun; 29(3):241-247. PubMed ID: 38863863
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy analysis of different pulmonary surfactants in premature infants with respiratory distress syndrome].
Xu H; Xu P
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Feb; 33(2):174-179. PubMed ID: 33729136
[TBL] [Abstract][Full Text] [Related]
31. Poractant alfa versus bovine lipid extract surfactant: prospective comparative effectiveness study.
Lemyre B; Lacaze-Masmonteil T; Shah PS; Bodani J; Doucette S; Dunn M; Louis D; Monterrosa L; Mukerji A; Schmölzer GM; Singh B; Wong J; Ye XY; Offringa M
J Perinatol; 2022 Apr; 42(4):468-475. PubMed ID: 35177795
[TBL] [Abstract][Full Text] [Related]
32. [Prophylaxis and treatment of respiratory distress syndrome with different surfactants].
Navas Serrano VM; Cuevas García MA; Vila Alvarez JA; Martínez Fernández V; Morcillo Sopena F; Valls I Soler A
An Esp Pediatr; 2002 Jan; 56(1):40-4. PubMed ID: 11792243
[TBL] [Abstract][Full Text] [Related]
33. Poractant Alfa Versus Beractant for Neonatal Respiratory Distress Syndrome: A Retrospective Cost Analysis.
Brown S; Hurren J; Sartori H
J Pediatr Pharmacol Ther; 2018; 23(5):367-371. PubMed ID: 30429690
[TBL] [Abstract][Full Text] [Related]
34. In vitro characterization and in vivo comparison of the pulmonary outcomes of Poractant alfa and Calsurf in ventilated preterm rabbits.
Guo X; Luo S; Amidani D; Rivetti C; Pieraccini G; Pioselli B; Catinella S; Murgia X; Salomone F; Xu Y; Dong Y; Sun B
PLoS One; 2020; 15(3):e0230229. PubMed ID: 32168331
[TBL] [Abstract][Full Text] [Related]
35. Porcine vs bovine surfactant therapy for preterm neonates with RDS: systematic review with biological plausibility and pragmatic meta-analysis of respiratory outcomes.
Tridente A; De Martino L; De Luca D
Respir Res; 2019 Feb; 20(1):28. PubMed ID: 30728009
[TBL] [Abstract][Full Text] [Related]
36. A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome.
Dani C; Talosi G; Piccinno A; Ginocchio VM; Balla G; Lavizzari A; Stranak Z; Gitto E; Martinelli S; Plavka R; Krolak-Olejnik B; Lista G; Spedicato F; Ciurlia G; Santoro D; Sweet D;
J Pediatr; 2022 Jul; 246():40-47.e5. PubMed ID: 35257740
[TBL] [Abstract][Full Text] [Related]
37. Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials.
Sánchez Luna M; Bacher P; Unnebrink K; Martinez-Tristani M; Ramos Navarro C
J Perinatol; 2020 Aug; 40(8):1121-1134. PubMed ID: 32051542
[TBL] [Abstract][Full Text] [Related]
38. Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS.
Ramanathan R
J Perinatol; 2006 May; 26 Suppl 1(Suppl 1):S51-6; discussion S63-4. PubMed ID: 16625226
[TBL] [Abstract][Full Text] [Related]
39. History of surfactant from 1980.
Halliday HL
Biol Neonate; 2005; 87(4):317-22. PubMed ID: 15985754
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary Complications in Premature Infants Using a Beractant or Poractant for Respiratory Distress Syndrome: A Retrospective Cohort Study.
Wong KL; Siu KL
Am J Perinatol; 2024 Apr; 41(5):641-648. PubMed ID: 35098502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
